ArticleFrontiers in digital health2026
A two-phase digital tool to predict and prevent post-transplant hyperuricemia.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-transplant hyperuricemia (PTHU) is a frequent and clinically significant metabolic complication among kidney transplant recipients. Current models lack personalized pre-transplant prevention strategies, and few studies define the optimal tacrolimus level for PTHU prevention. To address this unmet need, we developed and evaluated an integrated digital health tool consisting of a pre-operative risk-prediction algorithm and a post-operative tacrolimus dosing management module. Method: We enrolled 195 kidney transplant recipients. Pre-transplantation laboratory assessments and serial tacrolimus blood-concentration (Ctac) measurements longitudinally were conducted, while documenting adverse events. Logistic regression was used to identify the risk factors, and then incorporated into a nomogram. A subsequent dosing optimization algorithm was derived from these results. Results: We identified four independent risk factors-standard deviation of red blood cell distribution width (RDW-SD), prothrombin time activity (PTA), serum calcium, and Ctac. Notably, the model achieved strong discriminative performance, with AUROCs of 0.802 (95% CI 0.723-0.881, Conclusion: This study provides a pre-operative risk prediction model and a post-operative dosing tool that, used in tandem, can aid in the prevention of PTHU and the protection of renal allograft function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.